Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1998-08-05
2004-09-14
Lacourciere, Karen A. (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S006120, C435S325000, C435S091200
Reexamination Certificate
active
06790944
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a novel protein whose expression level fluctuates in leukocytes of IgA nephropathy patients in comparison with leukocytes of healthy persons, an antibody against the protein, DNA encoding the protein, methods for detecting the protein using the antibody, mRNA and DNA using a primer comprising a complementary nucleotide sequence to the DNA, and diagnosis and treatment of IgA nephropathy.
2. Brief Description of the Background Art
IgA nephropathy is a chronic glomerulonephritis which is characterized in that an IgA immune complex considered to be originated from blood deposits in glomerulus of the kidney. In Japan, the IgA nephropathy occupies 30% or more of primary renal diseases, and is the most common renal disease. Moreover, 15 to 30% of the patients with IgA nephropathy achieve renal failure due to poor prognosis. However, since the underlying cause of IgA nephropathy is still unclear, a fundamental therapeutic method has not been found. Additionally, definite diagnosis of IgA nephropathy imposes heavy burden on patients, because the method is carried out by removing a portion of the kidney by biopsy and recognizing deposition of the IgA immune complex in mesangium by means of an immunological staining.
It has been reported that about 50% of the patients with IgA nephropathy have a high blood IgA level [
Diseases of the Kidney,
5th edition (1993),
Nephron,
29, 170 (1981)]. It is considered that B cells relate to the production of IgA in blood and T cells relate to the regulation of the production. Furthermore, it has been reported that the production of cytokine, such as interleukin 4, interleukin 5, interleukin 6 or TGF-&bgr; (transforming growth factor-&bgr;), is high in peripheral T cells of IgA nephropathy patients in comparison with healthy persons [
Clinical
&
Experimental Immunology,
103, 125 (1996),
Kidney International,
46, 862 (1994))] and that integrin, such as VLA (very late activation)-4 and VLA-5, are strongly activated in peripheral lymphocytes of IgA nephropathy patients [
Nephrology, Dialysis, Transplantation,
10, 1342 (1995)].
On the basis of these facts, it is considered that, in IgA nephropathy, excessive IgA is produced due to abnormality in the immune system, the resulting IgA immune complex in blood deposits on the glomerulus, and the complement system is activated on the deposited IgA immune complex and the like to exert influence and cause disorders of the glomerulus. However, the cause of IgA nephropathy has not yet been determined.
SUMMARY OF THE INVENTION
Elucidation of the cause of IgA nephropathy, as well as a treatment or diagnosis which can reduce a burden on patients are long-sought. The present invention provides a novel protein which has been determined to have increased expression level in leukocytes of IgA nephropathy patients, as well as an antibody against the protein, DNA encoding the protein, methods for detecting the protein using the antibody, mRNA and DNA using the oligonucleotide comprising a complementary nucleotide sequence to the DNA, and diagnostic and therapeutic agents of IgA nephropathy.
The present invention relates to a protein comprising the amino acid sequence represented by SEQ ID NO:2; DNA encoding the protein of the present invention; DNA which comprises the nucleotide sequence represented by SEQ ID NO:1; and DNA which hybridizes with the DNA comprising the above nucleotide sequence under stringent conditions. Furthermore, the present invention relates to a recombinant vector which comprises the DNA and a vector; a transformant obtained by introducing the recombinant vector into a host cell; and a process for producing the protein, comprising culturing the transformant in a medium to produce and accumulate the protein of the present invention in the culture, and recovering the protein from the resulting culture.
Moreover, the present invention relates to a method for detecting the mRNA derived from the protein of the present invention using an oligonucleotide comprising a portion of the nucleotide sequence of the DNA of the present invention or a portion of the nucleotide sequence complementary to the DNA, for example, the oligonucleotide represented by SEQ ID NO:6 or NO:7; and IgA nephropathy diagnostic agents comprising the oligonucleotide.
Also, the present invention relates to a method for inhibiting expression of the protein of the present invention using an oligonucleotide comprising a portion of the nucleotide sequence of the DNA of the present invention or a portion of the nucleotide sequence complementary to the DNA, for example, the oligonucleotide represented by SEQ ID NO:6 or NO:7; and IgA nephropathy therapeutic agents comprising the oligonucleotide.
Additionally, the present invention relates to an antibody which specifically reacts with the protein of the present invention; a method for immunologically detecting the protein of the present invention using the antibody of the present invention; and IgA nephropathy diagnostic and therapeutic agents comprising the antibody.
REFERENCES:
patent: 5225326 (1993-07-01), Bresser et al.
patent: WO-95/14772 (1995-06-01), None
Hiller, L. et al., Genbank Accession No. N21024, Dec. 1995, Unpublished (1995).*
Hiller et al., Generation and Analysis of 280,000 Human Expressed Sequence Tags, 1996, Genome Research, vol. 6, pp. 807-828.*
Nagase et al. Accession No. o00234, D87078, Jul. 1997.*
Branch AD. TIBS 23, p. 45-50, Feb. 1998.*
Crooke ST, ed. Antisense Research and Application. Springer Press, p. 1-49, 1998.*
Kendrew J, ed. The Encyclopedia of Molecular Biology. Blackwell Science Inc. p. 503-505, 1994.*
Plenat F. Molecular Medicine Today. p. 250-257, Jun. 1996.*
Agrawal S. Tibtech. 14: 376-387, Oct. 1996.*
Biolabs Catalog 1988-1989, #1230, 1989.*
O'Hara, et al., “Homo sapiens mRNA for KIAA0099 Protein, partial cds.” (1997) Accession No. XP-002208794.
O'Hara, et al., “Homo sapiens mRNA for KIAA0235 protein, partial cds” (1994) Accession No. XP-002208795.
“Perspectives in Clinical Nephrology IGA Nephropathy”,Kidney International, vol. 47, No. 2 (1995), pp. 377-387 (XP-002940424).
Namie, et al., “Expression and Function of Fibronectin Receptors on Peripheral Mononuclear cells in IGA Nephropathy”,Nephrology Dialysis Transplantationvol. 10 (1995), pp. 1342-1347.
Nagase, et al., “Hypothetical protein KIAA0099 (Pumilio 1) (Fragment)”, 1996, Accession No. Q14671 XP-002208796.
DNA Research, vol.3 (Oct. 1996), pp. 321-329.
Ishiwata Tetsuyoshi
Kawabata Ayako
Kuga Tetsuro
Nagase Takahiro
Nakagawa Satoshi
Kyowa Hakko Kogyo Co. Ltd.
Lacourciere Karen A.
LandOfFree
DNA encoding IGA nephropathy indicating protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA encoding IGA nephropathy indicating protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding IGA nephropathy indicating protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3229849